Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from ...
Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from European and US regulatory agencies. The company offers validated GMP routes and regulatory approvals for various therapeutic areas, including fertility, eye care, glaucoma and pulmonary hypertension, enabling the development and market launch of its products.
Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from ...
Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from European and US regulatory agencies. The company offers validated GMP routes and regulatory approvals for various therapeutic areas, including fertility, eye care, glaucoma and pulmonary hypertension, enabling the development and market launch of its products.
Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from ...
Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from European and US regulatory agencies. The company offers validated GMP routes and regulatory approvals for various therapeutic areas, including fertility, eye care, glaucoma and pulmonary hypertension, enabling the development and market launch of its products.
Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from ...
Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from European and US regulatory agencies. The company offers validated GMP routes and regulatory approvals for various therapeutic areas, including fertility, eye care, glaucoma and pulmonary hypertension, enabling the development and market launch of its products.
Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from ...
Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from European and US regulatory agencies. The company offers validated GMP routes and regulatory approvals for various therapeutic areas, including fertility, eye care, glaucoma and pulmonary hypertension, enabling the development and market launch of its products.
Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from ...
Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from European and US regulatory agencies. The company offers validated GMP routes and regulatory approvals for various therapeutic areas, including fertility, eye care, glaucoma and pulmonary hypertension, enabling the development and market launch of its products.
Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from ...
Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from European and US regulatory agencies. The company offers validated GMP routes and regulatory approvals for various therapeutic areas, including fertility, eye care, glaucoma and pulmonary hypertension, enabling the development and market launch of its products.
Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from ...
Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from European and US regulatory agencies. The company offers validated GMP routes and regulatory approvals for various therapeutic areas, including fertility, eye care, glaucoma and pulmonary hypertension, enabling the development and market launch of its products.
KEY PRODUCTS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
Cayman Pharma is Europe's most reliable and versatile source for Prostaglandin APIs//FDA approved.
